Gonadal Pharmacology · Module 3 of 5

Hormone Therapy, SERMs, and GnRH Modulators

Menopause management, tissue-selective estrogen receptor modulators, and gonadotropin-releasing hormone pharmacology

The Women's Health Initiative must be read as two separate trials — the combined CEE+MPA arm showed increased breast cancer, coronary heart disease, and VTE, while the CEE-alone arm (hysterectomized women) showed no breast cancer increase and reduced hip fracture risk; the breast cancer signal belongs to medroxyprogesterone acetate, not to estrogen, and the most commonly used current regimen (transdermal estradiol + micronized progesterone) was never tested in the WHI.
Timing is decisive in hormone therapy — initiating within 10 years of menopause or before age 60 produces a favorable cardiovascular risk profile (the "timing hypothesis"), while initiating more than 10 years after menopause in older women with established atherosclerosis produces net cardiovascular harm; route selection also matters: transdermal estradiol bypasses portal first-pass and does not raise VTE risk, making it the preferred route in patients with VTE risk factors.
SERMs (selective estrogen receptor modulators) exploit tissue-specific differences in estrogen receptor co-regulator expression — tamoxifen blocks ERα in breast but acts as a partial agonist at uterine ERα (endometrial cancer risk) and bone; raloxifene blocks ERα in both breast and uterus (no endometrial cancer risk) while retaining bone agonism; this tissue selectivity is pharmacologically distinct from pure antagonism or pure agonism.
Tamoxifen is a prodrug — its primary active metabolite endoxifen is generated by CYP2D6; potent CYP2D6 inhibitors (paroxetine, fluoxetine) reduce endoxifen levels by up to 75%, potentially abolishing oncological benefit; when hot flushes require treatment in tamoxifen-treated patients, venlafaxine or gabapentin must be used instead of paroxetine or fluoxetine.
GnRH agonists and antagonists achieve the same endpoint (gonadal suppression) through opposite mechanisms — agonists cause receptor downregulation after an initial flare requiring antiandrogen cover in prostate cancer; antagonists block receptors immediately with no flare, enabling rapid titration and use of a GnRH agonist as an ovulation trigger in ART; oral antagonists (elagolix, relugolix) with built-in add-back (Myfembree) represent the first long-term medical options for endometriosis and fibroids.

Abbreviations: CEE = conjugated equine estrogens · MPA = medroxyprogesterone acetate · WHI = Women's Health Initiative · VTE = venous thromboembolism · SERM = selective estrogen receptor modulator · ERα = estrogen receptor alpha · GnRH = gonadotropin-releasing hormone · PCOS = polycystic ovary syndrome · VEGF = vascular endothelial growth factor · CYP2D6 = cytochrome P450 2D6 · ART = assisted reproductive technology · FSH = follicle-stimulating hormone · LH = luteinizing hormone

Hormone Therapy — WHI Evidence and Prescribing Rules

WHI — Two Arms, Two Profiles

Never Conflate CEE+MPA vs. CEE Alone

CEE + MPA (intact uterus): breast cancer ↑, coronary heart disease ↑, VTE ↑
CEE alone (hysterectomized): no breast cancer increase; hip fracture reduced
Breast cancer signal = MPA component, not estrogen alone
Transdermal estradiol + micronized progesterone: NOT tested in WHI — current regimens carry different risk profile

Timing Hypothesis and Route Selection

When and How to Prescribe

Start within 10 years of menopause or before age 60: favorable cardiovascular profile (ELITE trial)
Start >10 years after menopause: net cardiovascular harm — atherosclerosis already established
VTE risk factors: transdermal estradiol preferred — bypasses portal first-pass, no VTE increase
Intact uterus: must add progestin (endometrial protection)
Post-hysterectomy: estrogen alone (no progestin needed)
Breast cancer risk concern: micronized progesterone preferred over MPA (E3N cohort data)

Selective Estrogen Receptor Modulators — Tissue Effects

SERM	Breast Effect	Uterine Effect	Bone Effect	Key Clinical Point
Tamoxifen	ERα antagonist — blocks proliferation	Partial ERα agonist → endometrial cancer risk (monitor for uterine bleeding)	Partial agonist — maintains bone density	Prodrug: CYP2D6 → endoxifen. Avoid paroxetine/fluoxetine — reduces endoxifen 75%. Use venlafaxine or gabapentin for hot flushes.
Raloxifene	ERα antagonist	ERα antagonist — no endometrial cancer risk	ERα agonist — approved for osteoporosis	Preferred for breast cancer chemoprevention in postmenopausal women (STAR trial); no uterine cancer risk vs. tamoxifen
Ospemifene	ERα antagonist	Mild agonist — monitor endometrium with prolonged use	Neutral	Oral SERM for dyspareunia (vulvovaginal atrophy); systemic VTE risk; hot flushes common adverse effect

GnRH Agonists vs. Antagonists — Mechanism and Clinical Differences

GnRH Agonists — Leuprolide, Goserelin, Nafarelin

Downregulation After Initial Flare

Continuous stimulation → receptor downregulation → gonadotropin suppression
Onset: 2–4 weeks to achieve therapeutic suppression
Initial flare (weeks 1–2): transient sex hormone surge — clinically significant in prostate cancer (bone pain, urinary obstruction)
Prostate cancer: cover flare with antiandrogen for 4 weeks (bicalutamide)
Route: depot injection (1-, 3-, or 6-month formulations)
Bone mineral density loss limits use to 6 months without add-back; add-back extends to 12+ months safely

GnRH Antagonists — Elagolix, Relugolix, Cetrorelix

Immediate Suppression, No Flare

Competitive receptor blockade → immediate LH and FSH suppression — no flare period
Onset: hours; cessation: rapid recovery of gonadotropin secretion
Elagolix (oral): endometriosis — dose-dependent partial vs. complete suppression allows titration of estrogen effect
Relugolix (oral): prostate cancer (Orgovyx); faster testosterone recovery than leuprolide on discontinuation
Relugolix + estradiol + norethindrone acetate (Myfembree): fibroids — first approved long-term non-surgical option with built-in add-back
Enables GnRH agonist trigger in ART antagonist cycles (pituitary not downregulated)

Endometriosis and Uterine Fibroids — Treatment Hierarchy

Endometriosis — Estrogen-Dependent

Treatment Ladder

First-line: COCs, progestin-only (norethindrone, DMPA, implant), LNG-IUD — suppress endometrial implants with minimal systemic exposure
LNG-IUD: highly effective for dysmenorrhea and bleeding; preferred initial option where cavity not distorted
Second-line: GnRH agonists with add-back (6–12 months), or elagolix (titratable, oral)
Elagolix advantage: dose-dependent — 150 mg daily = partial suppression; 200 mg twice daily = near-complete suppression

Uterine Fibroids — Estrogen + Progesterone Dependent

Medical Options

LNG-IUD 52 mg: first-line for heavy menstrual bleeding when cavity not distorted by fibroids
GnRH agonists: reduce fibroid volume 30–60% preoperatively — surgical bridge only; rapid regrowth on discontinuation
Relugolix + add-back (Myfembree): first approved long-term medical option — reduces bleeding and fibroid volume sustainably
Tranexamic acid: adjunct for acute heavy bleeding episodes

Tamoxifen — CYP2D6 Drug Interaction Rule

Tamoxifen is a prodrug — its primary active metabolite endoxifen requires CYP2D6 for synthesis. Paroxetine and fluoxetine are potent CYP2D6 inhibitors that reduce endoxifen levels by up to 75%, potentially abolishing oncological benefit. This is a clinically critical drug interaction because hot flushes are common in tamoxifen-treated breast cancer patients who often ask for antidepressant treatment: venlafaxine (weak CYP2D6 inhibition) or gabapentin must be used instead. Paroxetine is absolutely contraindicated with tamoxifen.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 40: Estrogens, Progestins, and the Female Reproductive Tract	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 44: Estrogens and Progestins	McGraw-Hill; 2023
Rossouw JE, Anderson GL, Prentice RL, et al; WHI Investigators.	Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial	JAMA. 2002;288(3):321–333
Manson JE, Chlebowski RT, Stefanick ML, et al.	Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials	JAMA. 2013;310(13):1353–1368
Hodis HN, Mack WJ, Henderson VW, et al; ELITE Research Group.	Vascular effects of early versus late postmenopausal treatment with estradiol	N Engl J Med. 2016;374(13):1221–1231
Fournier A, Berrino F, Clavel-Chapelon F.	Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study	Breast Cancer Res Treat. 2008;107(1):103–111
Canonico M, Oger E, Plu-Bureau G, et al; ESTHER Study Group.	Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens	Circulation. 2007;115(7):840–845
Vinogradova Y, Coupland C, Hippisley-Cox J.	Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases	BMJ. 2019;364:k4810
Collaborative Group on Hormonal Factors in Breast Cancer.	Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence	Lancet. 2019;394(10204):1159–1168
Jordan VC.	Tamoxifen: a most unlikely pioneering medicine	Nat Rev Drug Discov. 2003;2(3):205–213
Goetz MP, Kamal A, Ames MM.	Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response	Clin Pharmacol Ther. 2008;83(1):160–166
Vogel VG, Costantino JP, Wickerham DL, et al; NSABP.	Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial	JAMA. 2006;295(23):2727–2741
Schally AV, Arimura A, Baba Y, et al.	Isolation and properties of the FSH and LH-releasing hormone	Biochem Biophys Res Commun. 1971;43(2):393–399
Surrey ES, Hornstein MD.	Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up	Obstet Gynecol. 2002;99(5 Pt 1):709–719
Taylor HS, Giudice LC, Lessey BA, et al.	Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist	N Engl J Med. 2017;377(1):28–40
Al-Hendy A, Lukes AS, Poindexter AN 3rd, et al.	Treatment of uterine fibroid symptoms with relugolix combination therapy	N Engl J Med. 2021;384(7):630–642
Dunselman GA, Vermeulen N, Becker C, et al; ESHRE.	ESHRE guideline: management of women with endometriosis	Hum Reprod. 2014;29(3):400–412